肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

重组人血管内皮抑制素治疗恶性浆膜腔积液临床应用专家共识

2020-09-30 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会 临床肿瘤学杂志.2020.25(9):849-856.

浆膜腔积液

为了更好地指导临床上合理地应用恩度治疗恶性浆膜腔积液，中国临床肿瘤学会( CSCO) 抗肿瘤药物安全管理专家委员会和血管靶向治疗专家委员会共同组织了相关领域的多学科专家学者，根据恩度治疗恶性浆膜腔积液

中文标题：

重组人血管内皮抑制素治疗恶性浆膜腔积液临床应用专家共识

发布机构：

中国临床肿瘤学会抗肿瘤药物安全管理专家委员会

发布日期：

2020-09-30

简要介绍：

为了更好地指导临床上合理地应用恩度治疗恶性浆膜腔积液，中国临床肿瘤学会( CSCO) 抗肿瘤药物安全管理专家委员会和血管靶向治疗专家委员会共同组织了相关领域的多学科专家学者，根据恩度治疗恶性浆膜腔积液的转化研究、临床试验以及真实世界的实践经验，参考国内、外有关文献，认真讨论，多次修改，形成了本专家共识，作为临床医师用药的重要参考

相关资料下载：
[AttachmentFileName(sort=1, fileName=重组人血管内皮抑制素治疗恶性浆膜腔积液临床应用专家共识_秦叔逵.pdf)] GetToolGuiderByIdResponse(projectId=1, id=25b8b1c001995164, title=重组人血管内皮抑制素治疗恶性浆膜腔积液临床应用专家共识, enTitle=, guiderFrom=临床肿瘤学杂志.2020.25(9):849-856., authorId=0, author=, summary=为了更好地指导临床上合理地应用恩度治疗恶性浆膜腔积液，中国临床肿瘤学会( CSCO) 抗肿瘤药物安全管理专家委员会和血管靶向治疗专家委员会共同组织了相关领域的多学科专家学者，根据恩度治疗恶性浆膜腔积液, cover=https://img.medsci.cn/20201023/1603466861563_2020535.jpg, journalId=0, articlesId=null, associationId=964, associationName=中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, associationIntro=null, copyright=0, guiderPublishedTime=Wed Sep 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>为了更好地指导临床上合理地应用恩度治疗恶性浆膜腔积液，中国临床肿瘤学会( CSCO) 抗肿瘤药物安全管理专家委员会和血管靶向治疗专家委员会共同组织了相关领域的多学科专家学者，根据恩度治疗恶性浆膜腔积液的转化研究、临床试验以及真实世界的实践经验，参考国内、外有关文献，认真讨论，多次修改，形成了本专家共识，作为临床医师用药的重要参考</p> </div> </div> </div>, tagList=[TagDto(tagId=17851, tagName=浆膜腔积液)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=17851, guiderKeyword=浆膜腔积液, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2111, appHits=150, showAppHits=0, pcHits=565, showPcHits=1960, likes=4, shares=16, comments=4, approvalStatus=1, publishedTime=Sat Oct 24 00:09:27 CST 2020, publishedTimeString=2020-09-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Oct 23 23:28:01 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 10:50:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=重组人血管内皮抑制素治疗恶性浆膜腔积液临床应用专家共识_秦叔逵.pdf)])
重组人血管内皮抑制素治疗恶性浆膜腔积液临床应用专家共识_秦叔逵.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1205793, encodeId=36021205e9360, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b05e2597625, createdName=mx186, createdTime=Fri Mar 25 09:33:08 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013317, encodeId=b399101331e8f, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b905522600, createdName=ms6980619036574494, createdTime=Tue Aug 31 22:31:34 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971035, encodeId=a4109e103561, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5b2517502, createdName=124d1424m59暂无昵称, createdTime=Sat Jun 05 08:06:25 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896942, encodeId=f07e8969427b, content=很实用，临床指导, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PoZNgQYECm9EACoEhKXfFG8jvuG6NiaiaZiaSm2icb5c71MCHVXDOmE9huzaACteveKicMD7QIzh2Q3D5O5m9M1Rj4g/132, createdBy=6c992493334, createdName=天蓝00000, createdTime=Wed Nov 04 21:04:19 CST 2020, time=2020-11-04, status=1, ipAttribution=)]
    2022-03-25 mx186

    很实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1205793, encodeId=36021205e9360, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b05e2597625, createdName=mx186, createdTime=Fri Mar 25 09:33:08 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013317, encodeId=b399101331e8f, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b905522600, createdName=ms6980619036574494, createdTime=Tue Aug 31 22:31:34 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971035, encodeId=a4109e103561, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5b2517502, createdName=124d1424m59暂无昵称, createdTime=Sat Jun 05 08:06:25 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896942, encodeId=f07e8969427b, content=很实用，临床指导, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PoZNgQYECm9EACoEhKXfFG8jvuG6NiaiaZiaSm2icb5c71MCHVXDOmE9huzaACteveKicMD7QIzh2Q3D5O5m9M1Rj4g/132, createdBy=6c992493334, createdName=天蓝00000, createdTime=Wed Nov 04 21:04:19 CST 2020, time=2020-11-04, status=1, ipAttribution=)]
    2021-08-31 ms6980619036574494

    很实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1205793, encodeId=36021205e9360, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b05e2597625, createdName=mx186, createdTime=Fri Mar 25 09:33:08 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013317, encodeId=b399101331e8f, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b905522600, createdName=ms6980619036574494, createdTime=Tue Aug 31 22:31:34 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971035, encodeId=a4109e103561, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5b2517502, createdName=124d1424m59暂无昵称, createdTime=Sat Jun 05 08:06:25 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896942, encodeId=f07e8969427b, content=很实用，临床指导, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PoZNgQYECm9EACoEhKXfFG8jvuG6NiaiaZiaSm2icb5c71MCHVXDOmE9huzaACteveKicMD7QIzh2Q3D5O5m9M1Rj4g/132, createdBy=6c992493334, createdName=天蓝00000, createdTime=Wed Nov 04 21:04:19 CST 2020, time=2020-11-04, status=1, ipAttribution=)]
    2021-06-05 124d1424m59暂无昵称

    很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1205793, encodeId=36021205e9360, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b05e2597625, createdName=mx186, createdTime=Fri Mar 25 09:33:08 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013317, encodeId=b399101331e8f, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b905522600, createdName=ms6980619036574494, createdTime=Tue Aug 31 22:31:34 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971035, encodeId=a4109e103561, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5b2517502, createdName=124d1424m59暂无昵称, createdTime=Sat Jun 05 08:06:25 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896942, encodeId=f07e8969427b, content=很实用，临床指导, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PoZNgQYECm9EACoEhKXfFG8jvuG6NiaiaZiaSm2icb5c71MCHVXDOmE9huzaACteveKicMD7QIzh2Q3D5O5m9M1Rj4g/132, createdBy=6c992493334, createdName=天蓝00000, createdTime=Wed Nov 04 21:04:19 CST 2020, time=2020-11-04, status=1, ipAttribution=)]
    2020-11-04 天蓝00000

    很实用，临床指导

    0

拓展阅读

浆膜腔积液细胞形态学检验中国专家共识（2020）

中国检验科相关专家小组（统称） · 2020-11-30